On Tuesday, H.C. Wainwright maintained its Buy rating and $30.00 price target on Voyager Therapeutics (NASDAQ:VYGR) stock, a biotechnology firm specializing in the development of gene therapies for central nervous system (CNS) diseases.
The firm's endorsement follows Voyager's recent announcement of their second quarter financial results for 2024 and updates on their CNS-focused pipeline and adeno-associated virus (AAV) capsid discovery platform, TRACER.
Voyager Therapeutics is evaluating VY7523, an anti-tau monoclonal antibody, in a Phase 1a trial with healthy volunteers. Top-line safety and pharmacokinetic data from this trial are expected in the first half of 2025. Additionally, the company plans to initiate a Phase 1b trial with VY7523 in patients with early Alzheimer's disease (AD) in 2025, with tau PET tracing data anticipated in the second half of 2026.
The company has also completed a pre-investigational new drug (IND) meeting with the FDA and has initiated Good Laboratory Practice (GLP) toxicology studies to support an IND filing for VY9323. This wholly-owned gene therapy aims to silence the SOD1 gene in patients with SOD1-driven amyotrophic lateral sclerosis (SOD1-ALS) and is projected to be ready for filing by mid-2025.
Furthermore, three additional gene therapy programs are on track for IND filings in 2025. These include partnered programs targeting GBA1 and Friedreich's ataxia (FA), as well as the wholly-owned SOD1-silencing gene therapy program for SOD1-ALS.
These filings are expected not only further to validate Voyager's gene therapy programs but also provide milestones that could fund the company's internal pipeline.
Looking ahead, Voyager's tau-silencing gene therapy program for Alzheimer's disease, which uses a vectorized siRNA targeting tau, is on track for an IND filing in 2026.
With these developments in mind, H.C. Wainwright reaffirmed its positive stance on Voyager Therapeutics' stock, anticipating updates that could influence its valuation.
InvestingPro Insights
As Voyager Therapeutics forges ahead with its clinical trials and gene therapy programs, investors are closely monitoring the company's financial health and market performance. According to InvestingPro data, Voyager Therapeutics holds a market capitalization of approximately $363.19 million, signaling a moderate size within the biotech industry. Despite the challenges faced by the company, including a notable sales decline of 26.22% over the last twelve months as of Q2 2024, Voyager's balance sheet reflects a strategic advantage with more cash than debt, providing a cushion for its ambitious R&D endeavors.
InvestingPro Tips reveal that while analysts have revised their earnings expectations downwards for the upcoming period, and anticipate a sales decline in the current year, the company's stock is currently trading at a low revenue valuation multiple. This could suggest a potential undervaluation relative to its sales. However, it is also trading at a high earnings multiple, which may reflect investor optimism about its long-term prospects. Additionally, Voyager has been profitable over the last twelve months, which is an encouraging sign amidst the anticipation of net income dropping this year.
For investors looking for more in-depth analysis, there are 10 additional InvestingPro Tips available, which can be found at https://www.investing.com/pro/VYGR. These insights could prove valuable for those considering an investment in Voyager Therapeutics as the company navigates the complex landscape of CNS-focused gene therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.